Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
abrdn U.S. Small Cap Equity Fund abrdn Inc. | “At the stock level, Corcept Therapeutics detracted from performance. The company's shares dropped sharply after its hypercortisolism drug failed to secure FDA approval, raising concerns about pipeline strength and future growth prospects. The setback increased uncertainty around the company's ability to translate its research into approved therapies. BSD Analysis: Corcept Therapeutics is entering a pivotal year in 2026 as it nears the potential commercial launch of relacorilant, its next-generation treatment for Cushing's syndrome. The investment case is currently balanced between the steady, 20% annual revenue growth of its flagship product, Korlym, and the high-upside potential of its oncology pipeline. For 2026, the company is preparing for a dedicated oncology sales force launch following anticipated approvals in the ovarian cancer space, where relacorilant has shown strong survival benefits. While the company recently faced a regulatory delay in the Cushing's space, its robust cash flow from Korlym provides a significant cushion to fund ongoing clinical trials and legal defenses of its patent portfolio. Analysts project that risk-adjusted sales could reach nearly 2 billion dollars by 2031, suggesting substantial long-term value from current levels. For investors, Corcept offers exposure to a profitable biotech with a deep pipeline of selective cortisol modulators for metabolic and oncological indications.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
